The Genetics of Pneumothorax. by Boone, Philip M et al.
1The Genetics of Pneumothorax
Philip M. Boone, MD, PhD,1,2 Rachel M. Scott, BA,3 Stefan J. Marciniak, PhD, MB BChir, FRCP, 
MA,3, 4 Elizabeth P. Henske, MD,5, † Benjamin A. Raby, MD, MPH5, 6, †, *
1) Harvard Genetics Training Program, Boston, MA, USA; 
2) Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA;
3) Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK; 
4) Division of Respiratory Medicine, Addenbrooke’s Hospital, Cambridge, UK; 
5) Pulmonary Genetics Center, Division of Pulmonary and Critical Care Medicine, Brigham and 
Women's Hospital, Harvard Medical School, Boston, MA, USA; 
6) Channing Division of Network Medicine, Department of Medicine, Brigham and Women's 
Hospital, Boston, MA, USA. 
†Equal contribution.
*Correspondence:
Dr. Benjamin Raby
Department of Medicine, Division of Pulmonary and Critical Care Medicine
Brigham and Women's Hospital
Harvard Medical School
181 Longwood Ave, Rm 447
Boston, MA 02115
Tel: +1 (617) 525-2739
Fax: +1 (617) 525-0958
E-mail: rebar@channing.harvard.edu
Key words: Pneumothorax, genetics, familial spontaneous pneumothorax, FLCN gene, Birt-
Hogg-Dubé syndrome, Marfan syndrome
Page 1 of 50  AJRCCM Articles in Press. Published on 25-January-2019 as 10.1164/rccm.201807-1212CI 
 Copyright © 2019 by the American Thoracic Society 
2Abstract
A genetic influence on spontaneous pneumothoraces – those occurring without a traumatic 
or iatrogenic cause – is supported by several lines of evidence: 1) Pneumothorax can cluster in 
families (i.e. familial spontaneous pneumothorax); 2) Mutations in the FLCN gene have been 
found in both familial and sporadic cases; and 3) Pneumothorax is a known complication of several 
genetic syndromes. Herein we review known genetic contributions to both sporadic and familial 
pneumothorax. We summarize the pneumothorax-associated genetic syndromes, including Birt-
Hogg-Dubé syndrome, Marfan syndrome, vascular (type IV) Ehlers-Danlos syndrome, alpha-1-
antitrypsin deficiency, tuberous sclerosis complex/lymphangioleiomyomatosis (LAM), Loeys-
Dietz syndrome, cystic fibrosis, homocystinuria, and cutis laxa, among others. At times, 
pneumothorax is their herald manifestation. These syndromes have serious potential 
extrapulmonary complications (e.g. malignant renal tumors in Birt-Hogg-Dubé syndrome), and 
surveillance and/or treatment is available for most disorders; thus, establishing a diagnosis is 
critical. To facilitate this, we provide an algorithm to guide the clinician in discerning which cases 
of spontaneous pneumothorax may have a genetic or familial contribution, which cases warrant 
genetic testing, and which cases should prompt an evaluation by a geneticist. 
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Spontaneous pneumothoraces are defined by air in the pleural space arising from neither 
trauma nor an iatrogenic cause. An anatomic or mechanical cause is identifiable in all cases of 
secondary spontaneous pneumothorax, which by definition arise from clinically recognizable 
underlying lung disease (e.g. tuberculosis). Even in primary spontaneous pneumothorax, defined 
by a lack of overt lung disease, emphysema-like anomalies (blebs, cysts, or bullae) are observed 
at surgery or on CT in most cases (1). Additional anatomic associations include being taller and 
thinner than average (2). Smoking is the primary environmental risk factor for primary 
spontaneous pneumothorax (3).
Several lines of evidence support genetic contributions to pneumothorax. Foremost are 
familial clustering, observed in 10-12% of cases, and the finding of gene mutations in both familial 
and sporadic cases. Additionally, pneumothorax is a feature of several Mendelian disorders, for 
example Birt-Hogg-Dubé and Marfan syndromes. 
In this review, we discuss known genetic contributions to both sporadic and familial 
pneumothorax and summarize the pneumothorax-associated genetic syndromes, all of which have 
serious potential complications and of which pneumothorax is occasionally the presenting feature. 
We provide an algorithm to guide the clinician in discerning which cases of spontaneous 
pneumothorax may have a genetic or familial contribution, and which of these cases should prompt 
genetic testing and/or evaluation by a geneticist. 
Sporadic pneumothorax
Primary spontaneous pneumothoraces occur without a family history in the majority (88-
90%) of cases (4, 5). We refer to these non-familial cases as sporadic pneumothorax. 
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Birt-Hogg-Dubé syndrome (BHDS). The BHDS phenotype includes lung cysts and pneumothorax 
in addition to renal cancer and skin findings, so investigators hypothesized that some variants in 
this gene might lead to a lung-only phenotype. No mutations were identified among ten sporadic 
cases screened by FLCN sequencing (6). However, among 92 sporadic pneumothorax patients 
screened for sequence errors and deletions, five (5%) had FLCN mutations (5). FLCN promoter 
methylation changes do not explain FLCN-negative sporadic pneumothorax (7).
Several additional studies of spontaneous pneumothorax have been reported that did not 
adequately enumerate family background. Nonetheless, if one were to assume that the majority of 
these cases are sporadic (supported by the higher prevalence of sporadic over familial 
pneumothorax), then these studies of all comers can provide insights regarding the role of genetics 
in sporadic pneumothorax:
To investigate whether mutations in the genes for additional pneumothorax-associated 
syndromes explain isolated pneumothorax, Zhang et al. screened for point mutations and deletions 
in FBN1, COL3A1, CBS , SERPINA1 , TSC1 and TSC2 , and FLCN (8). Three of 21 subjects had 
predicted-pathogenic mutations: two (10%) in FLCN and one (5%) in FBN1. Three variants of 
uncertain significance (one in FBN1, TSC1, and FLCN) were also found. While blebs and 
emphysema-like changes in spontaneous pneumothorax are typically apical (1), BHDS features 
predominately lower-lobe cysts (9, 10). To investigate whether non-apical lung cysts might herald 
FLCN mutations among patients with spontaneous pneumothorax, Johannesma et al. screened 40 
non-familial and familial SP patients with chest CT (11); indeed, all three subjects with cysts below 
the carina had FLCN mutations. To determine whether common genetic variants play a role in 
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pneumothorax (12). No SNPs met the Bonferroni correction threshold in the replication dataset. 
Familial pneumothorax 
10-12% of patients with spontaneous pneumothorax have a family history, termed familial 
spontaneous pneumothorax (FSP) (4, 5). The male:female ratio in FSP is 1.7:1 (4), less skewed 
than for all spontaneous pneumothoraces (2.1-6.2:1) (13-16). The risk of recurrent pneumothorax 
may be higher in FSP (68-72%) (6, 17) than in sporadic pneumothorax (13-54%) (11-13, 18), 
although the studies arriving at these recurrence rates differ in methodology, making the 
comparison imperfect. A higher recurrence rate when a family history is known could argue for 
surgical intervention after the first pneumothorax (19, 20). 
While some FSP families are identifiably autosomal dominant (AD) (Fig. 1a), in others the 
inheritance pattern is ambiguous (21). Indeed, among 29 FSP pedigrees, all were consistent with 
AD inheritance with a penetrance of 21% in females and 50% in males, but many of the pedigrees 
could also follow an X-linked recessive model (Fig. 1b) (4). 
Several attempts have been made to map the genetic cause(s) of FSP. In three FSP families, 
pneumothorax did not segregate with FBN1, the disease gene for Marfan syndrome (22). Linkage 
to the HLA-A2B40 haplotype exists in some families (23, 24) but not others (17, 25). In a large 
FSP family, CT scans revealed multiple asymptomatic family members with bullae randomly 
distributed throughout the lungs, transmitted in an AD pattern (Fig. 1c) (26). A heterozygous, 
predicted-truncating mutation was found in FLCN, the disease gene for Birt-Hogg-Dubé syndrome 
(BHDS). The penetrance of bullae in mutation carriers was 100%; for pneumothorax it was ~40%. 
The prevalence of FLCN mutations in FSP is 17-50% (5, 6). 
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of FSP is likely caused by mutations in one or more yet-undescribed disease genes. By definition, 
FSP families do not manifest renal or dermatological findings of BHDS. It is unknown what 
contributes to the full BHDS vs restricted FSP phenotype. 
Genetic syndromes predisposing to pneumothorax
Pneumothorax is at times a feature of a multisystem genetic syndrome (Table 1, Figure 2). 
These can be divided into three mechanistic classes (27): 1) those arising from mutations in tumor 
suppressor genes; 2) connective tissue disorders; and 3) those in which normal lung architecture 
is effaced. Given that these syndromes have serious, often-preventable complications, it is essential 
to make the correct diagnosis when pneumothorax is the presenting manifestation.
Syndromes related to tumor suppressor genes
Birt-Hogg-Dubé syndrome
Birt-Hogg-Dubé syndrome (BHDS) is an autosomal dominant condition caused by 
heterozygous mutations in FLCN, encoding folliculin (28). The full BHDS phenotype includes 
skin lesions, kidney cancer, lung cysts, and pneumothorax (Fig. 2a-c) (29). Incomplete and age-
dependent penetrance of features is characteristic (30). Skin findings include fibrofolliculomas 
(hamartomas of hair follicles) and trichodiscomas (tumors of the hair disk) (Fig. 2a) (29). These 
lesions are clinically identical, appearing as small, dome-shaped papules typically on the face, 
neck, chest, back, and arms. Skin tags are also observed frequently. Renal cancer subtypes include 
hybrid oncocytic/chromophobe tumors, chromophobe carcinomas, clear cell carcinomas, 
oncocytomas, and papillary renal cell carcinomas (31); their combined prevalence was estimated 
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NIH cases (30). Screening for renal tumors via imaging is the key intervention for BHDS; however, 
there is to date no concensus regarding the optimal modality (e.g. MRI, contrast CT, ultrasound) 
or the timing of imaging (i.e. earliest age, interval between tests), although algorithms have been 
suggested (29, 32). Although some authors have suggested colorectal cancer as a feature of BHDS 
(33), it is not an accepted part of the phenotype (29, 32, 34).
The lung cysts of BHDS tend to be basal (below the carina) and subpleural (Fig. 2b-c) (9, 
34). They vary in number and size, and most are non-spherical (9). Pulmonary cysts in BHDS have 
a penetrance of 83-100% (30, 34-37), while they are detected in 10% of unaffected control family 
members (34). BHDS cysts are usually asymptomatic, and spirometry is typically normal.
The prevalence of pneumothorax in BHDS is 22-41% (30, 34-38). Pneumothoraces in 
BHDS tend to arise in early- to mid-adulthood (37) but can affect children (39). They can be the 
presenting sign of BHDS (40). They are often recurrent (40-75%; (35, 37)). Resection or 
pleurodesis have been suggested after first-time pneumothorax in BHDS (41, 42).
Among BHDS patients, risk factors for pneumothorax include family history of 
pneumothorax (36), larger cyst size and number (37), extent of lower lung disease (35), flying (42, 
43), and scuba diving (43). Curiously, smoking is not a risk factor (32, 37). There is no genotype-
phenotype correlation nor modifier gene known to affect pneumothorax risk in BHDS (36). 
How FLCN mutations lead to cyst formation is unknown. One proposal is based on the 
observation that folliculin is involved in cell:cell adhesion via the desmosomal protein 
PKP4/p0071 (44, 45); this suggests that poor stretch tolerance to lung pressure may allow cyst 
formation (46). 
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Pulmonary lymphangioleiomyomatosis (LAM) is a progressive lung disease involving 
infiltration of the alveolar septa with smooth muscle-like LAM cells and the development of cysts 
that compromise normal lung parenchyma (47). LAM is typically diagnosed in young adulthood 
(48) and affects almost exclusively females – a presumed effect of estrogen (49-52). LAM occurs 
both sporadically and in association with tuberous sclerosis complex (TSC), an autosomal 
dominant genetic syndrome caused by germline loss-of-function mutations in TSC1 (encoding 
hamartin) or TSC2 (encoding tuberin)  (53, 54). Multitudinous clinical findings are possible in 
TSC (Table 1; Fig. 2q-y), affecting the brain, skin, abdominal viscera, heart, eyes, mouth, and 
lung. The lung phenotypes include LAM and micronodular pneumocyte hyperplasia. Among LAM 
patients, TSC patients (TSC-LAM) make up 15%, while the remaining 85% are sporadic (48). A 
very small number of men have LAM, all of whom have TSC-LAM (55).
TSC is a syndrome of hamartomas, explained by hamartin’s and tuberin’s role in regulating 
cell growth and division via the mTORC1 and other pathways (56). Although women with 
sporadic LAM lack germline mutations in TSC1/2, mosaic inactivating mutations in these genes 
are found in the pulmonary LAM cells of most patients (57-60). Nearly 30% of sporadic LAM 
patients have renal angiomyolipomas (48), a feature of TSC, which contain TSC2 mutations (57). 
The same TSC2 mutation is found in the angiomyolipoma and the LAM cells (57). In addition, 
LAM can recur after lung transplantation, and the recurrent LAM cells carry the original TSC2 
mutation (61). These findings suggest that LAM is a low-grade, metastatic neoplasm (62).  
Pneumothorax is the most common presenting sign of LAM (~1/3 of cases) (48). Other 
presenting features include shortness of breath, wheezing, and abnormal imaging including diffuse 
reticular pattern on X-ray and diffuse interstitial changes with infiltrates and cysts on CT (48). 
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reveals cystic changes consistent with LAM in 34-81% of women and 0-10% of men with TSC 
(63-65). With progression, LAM can cause chest pain, cough, hemoptysis, pleural effusions 
including chylous effusions, airway obstruction demonstrated via spirometry, and respiratory 
failure (48). Beyond imaging, the diagnosis of LAM is aided by lung biopsy, lymph node biopsy, 
and the serum biomarker VEGF-D (66-70).
The lifetime incidence of pneumothorax in LAM is 56-66% (48, 71, 72). Pneumothoraces 
are recurrent in 73-77% of patients (72, 73), with a mean number of 4.4 +/-0.5 (48). Risk factors 
for pneumothorax in LAM are prior pneumothorax (72), faster rate of FEV1 decline (71), and 
larger cyst size (71). Individuals with a prior pneumothorax had lower VEGF-D levels (74). 
Chronic loculated pneumothoraces are not worsened by flight, leading to the recommendation to 
avoid flight only in LAM patients with recent pneumothorax or current symptoms of 
pneumothorax (75). Pregnancy exacerbates respiratory symptoms in some women with LAM (48) 
and appears to be a risk factor for pneumothorax (76), however a lack of prospective studies makes 
the risk difficult to quantify. Polymorphisms in extracellular matrix proteins (collagen, elastin, 
matrix metalloproteinase-1) were not associated with pneumothorax in one study (71). 
The mTORC1 inhibitor sirolimus (Rapamycin) lowers the rate of decline of FEV1 in 
women with LAM (77). This intervention is based on the discovery that TSC2 mutations result in 
mTORC1 hyperactivation. Treatment with sirolimus is usually continued indefinitely since lung 
function was proven to decline after discontinuation. The impact of sirolimus on pneumothorax 
risk is unknown. Other treatments for LAM include oxygen, lung transplantation, and avoiding 
both smoking and estrogen supplementation (49, 66). Progesterone derivatives have been used 
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therapeutically (78) but without definitive benefit (48, 79). Pleurodesis is recommended after the 
first pneumothorax (67, 72) because of the likelihood of recurrence. 
Syndromes of disordered connective tissue 
Marfan Syndrome
Marfan syndrome is an autosomal dominant condition caused by heterozygous mutations 
in FBN1, encoding fibrillin 1. Marfan syndrome features include tall stature, thin body habitus, 
long limbs resulting in decreased upper segment to lower segment ratio, arachnodactyly, chest wall 
deformity, scoliosis, lens dislocation, and dilation/dissection/aneurysm/rupture of the aorta (Fig. 
2d-i) (80). Screening and treatment for cardiovascular complications is the primary intervention in 
the disorder. Pulmonary features of Marfan syndrome can include congenital malformations (e.g. 
rudimentary middle lobe), cysts, emphysema, and pneumothorax (81). Large total and residual 
lung volumes may be present (82). 
Apical blebs/bullae were found in Marfan syndrome patients at a rate of 8.9% with X-ray 
and 10% by CT (83). As 0-15% of healthy individuals have emphysema-like lesions including 
bullae by CT scan (1, 84) and 6% have blebs at surgery (85), it is unclear if these lung lesions are 
enriched in Marfan syndrome. 
Pneumothorax is enriched among Marfan syndrome patients, estimated at 4-11% (83, 86, 
87). Pneumothorax is one of the criteria of the Marfan systemic score (80). Among 8 patients, the 
median number of pneumothoraces was 1 (range 1-3) (83). Blebs or bullae are a risk factor for 
pneumothorax; pectus excavatum and smoking are not (83). Despite some familial clustering (88, 
89), no genotype-phenotype correlation for pneumothorax is known (83). 
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At times, pneumothorax is the presenting feature of Marfan syndrome (90). Among 10 
sporadic pneumothorax patients screened for the syndrome via hand x-rays (for arachnodactyly) 
and clinical exam, four had “possible” Marfan syndrome and one had “full-fledged” disease (91). 
One of 21 (5%) sporadic pneumothorax patients had a stop-gain mutation in FBN1 (8).
In the lung, fibrillin-containing microfibrils associate with elastin to help form elastic fibers. 
In a Marfan syndrome mouse model, age-dependent alveolar destruction occurs and appears to 
involve aberrant TGF-β signaling (92, 93). It is unclear in patients whether skeletal shape, lack of 
fibrillin, altered elastin, altered TGF-β signaling, or a combination leads to blebs/bullae and/or 
pneumothorax. 
Vascular Ehlers-Danlos syndrome
Ehlers-Danlos syndrome (EDS) is a family of connective disorders mostly resulting from 
mutant collagens or related proteins (94). Of these subtypes, pneumothorax is a feature only of 
vascular EDS (type IV; vEDS). 
vEDS is autosomal dominant, caused by heterozygous mutations in COL3A1, encoding the 
sole subunit of the homotrimeric type III collagen (95). vEDS can have fatal complications 
including rupture of arteries, the uterus, and intestines (96). Arterial rupture may be preceded by 
aneurysms or dissection (96). Other features include thin, translucent skin (Fig. 2j), characteristic 
facial features, easy bruising, clubfoot, congenital hip dislocation, lax small joints, carotid-
cavernous sinus fistula, and pulmonary features  (96). Screening and prevention incudes periodic 
imaging of the heart and vessels, blood pressure control, counseling regarding the risks of uterine 
rupture in pregnancy, and avoidance of colonoscopy and elective invasive arteriography (97). 
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Pulmonary complications of vEDS include cavitary lesions, cysts, bullae, fibrous nodules, 
pneumothorax, hemo-pneumothorax, and pulmonary hemorrhage (98, 99). Type III collagen in the 
lung is expressed in vessels and parenchymal fibroblasts (100). Thus, pulmonary complications of 
vEDS are proposed to result from poor tissue integrity (101, 102). The fibrous nodules, or fibrous 
pseudotumors, feature osseous metaplasia and may result from inefficient repair after injury to the 
pulmonary vessels or interstitium, with type I collagen favored over the absent type III collagen 
(99, 103-105).
 Pneumothorax (99, 106, 107) or hemopneumothorax (108) can be the presenting symptom 
of vEDS. The penetrance of either pneumothorax or hemothorax in vEDS was 16% in a series 
diagnosed clinically (97); of individuals diagnosed molecularly, pneumothorax prevalence was 80% 
(109). There is no known genotype-phenotype correlation for vEDS. Standard treatment of 
pneumothorax has worked (98). 
Loeys-Dietz syndrome
Loeys-Dietz syndrome is an autosomal dominant genetic disorder caused by mutations in 
TGFBR2, TGFBR1, SMAD3, TGFB2, and TGFB3. SMAD2 is a provisional gene. These genes 
encode components of the TFG-β signaling pathway. Pneumothorax is an occasional feature of 
Loeys-Dietz syndrome (110). It has been described once as the presenting feature (111). Other 
features are vascular (arterial aneurysms, dissections, and tortuosity), skeletal (pectus excavatum 
or carinatum, joint laxity or contractures, cervical spine instability, scoliosis, arachnodactyly, club 
foot), craniofacial (bifid uvula [Fig. 2k] or cleft palate, hypertelorism, craniosynostosis), cutaneous 
(translucent skin, dystrophic scars, easy bruising), and uterine (rupture during pregnancy) (112). 
Vascular features lead to premature death (112).  
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Homocystinuria
Homocystinuria is an autosomal recessive metabolic disorder caused by biallelic mutations 
in CBS, which encodes cystathionine β-synthase (113). Features are skeletal (tall stature with long 
limbs, scoliosis, pectus excavatum), ocular (lens dislocation, myopia), vascular (blood clots), CNS 
(intellectual disability, seizures), and cutaneous (hypopigmentation, livedo reticularis, malar flush) 
(Fig. 2o-p) (113). Plasma homocysteine and methionine are markedly elevated, and the condition 
can be diagnosed via elevated methionine on the newborn screen. (113) Therapy exists in the form 
of a methionine-restricted diet, supplementation with folate, B12, B6 (if responsive), betaine, and 
in certain circumstances anti-coagulation (113). Pneumothorax has been reported (114); the 
incidence is unknown. It has once been the presenting feature (115).  
Cutis laxa
Cutis laxa describes loose, redundant, hypoelastic skin particularly over the neck, hands, 
groin, face, and trunk (Fig. 2n). It is a feature of at least 10 genetic syndromes (116). Several of 
the cutis laxa syndromes display early-onset emphysema, including autosomal dominant cutis laxa 
(ELN gene), autosomal recessive cutis laxa Ia/Ib (FBLN4/FBLN5 genes), and Urban-Rifkin-Davis 
syndrome (LTBP4 gene). Pneumothorax has been reported occasionally in patients with cutis laxa 
syndromes (117), more frequently among the subtypes that feature emphysema (118, 119). The 
incidence of pneumothorax is unknown, and pneumothorax has never been reported as the 
presenting symptom of a cutis laxa syndrome. 
Syndromes that efface normal lung architecture
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Alpha-1-antitrypsin deficiency
Alpha-1-antitrypsin deficiency (A1AT deficiency) is an autosomal recessive disease 
caused by mutations in SERPINA1 (120). Its protein product, alpha-1 antitrypsin, inhibits the 
protease neutrophil elastase in the lungs. Individuals with bi-allelic mutations that in combination 
reduce the circulating levels or activity of A1AT to below ~35% of normal can have early-onset 
chronic obstructive pulmonary disease  (Fig. 2l) (120). The typical pathology is a progressive, 
panacinar, predominantly lower-lobe emphysema presenting in early to mid-adulthood (121). 
Other lung findings can include chronic bronchitis and bronchiectasis (122), apical bullae (123), 
and pneumothorax. 
Extrapulmonary complications include neonatal cholestatic jaundice, cirrhosis, and risk of 
hepatocellular carcinoma, resulting from polymerization of certain mutant forms of A1AT in the 
endoplasmic reticulum of hepatocytes (124). Panniculitis – painful inflammatory skin 
nodules/weeping lesions (Fig. 2m) – and vasculitis have also been reported (120). 
The incidence of pneumothorax in A1AT deficiency is unknown (125, 126), however of 
patients homozygous for the most common mutant allele, Pi*Z, 2-3% die of pneumothorax (126, 
127). Because pneumothorax can occasionally be the presenting symptom of A1AT deficiency 
(128, 129), several authors have screened for A1AT deficiency among patients with spontaneous 
pneumothorax: Estimates of A1AT range from 0 to 8% (1, 130-133). Although smoking is an 
important risk factor for lung disease progression (134) and death (127) in A1AT deficiency, its 
effect on pneumothorax risk is unknown. Also unknown is whether genotype or augmentation 
therapy (infusions of A1AT) can impact pneumothorax incidence or recurrence.
Cystic fibrosis
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Cystic fibrosis (CF) is caused by biallelic mutations in CFTR. Complications are 
gastrointestinal (meconium ileus, malabsorption, failure to thrive, pancreatic insufficiency and 
pancreatitis), reproductive (male infertility), and respiratory. Lung findings derive from thickened 
mucus affecting the mucociliary elevator and include recurrent infections, inflammation, 
bronchiectasis, cysts/cavitations, air trapping, hemoptysis, and pneumothorax (135). 
Pneumothorax as a herald sign of CF is probably rare because: 1) it is a late feature of the disease 
(136); and 2) CF is screened for in newborns in countries where it is prevalent, so the diagnosis is 
often made at birth. 
Incidence of pneumothorax among CF patients was 2% in children over a 15-year interval 
(137) and 3% in all ages over a 10-year period (136). Lifetime prevalence was estimated at 8% 
during the 1950s-80s (138). Specific risk factors for pneumothorax in CF include: older age; FEV1 
<30% predicted; infection with P. aeruginosa, B. cepacia, or Aspergillus; allergic 
bronchopulmonary aspergillosis; massive hemoptysis; enteral feeding; and pancreatic 
insufficiency (136). Recurrence is 50-90% ipsilaterally and 46% contralaterally (136, 139). A 
pneumothorax carries an attributable mortality of 6-14% (140).
Mechanically, pneumothorax risk in CF may derive from effacement of normal lung 
structures, altered airflow dynamics, air trapping, use of inhaled medications, or noninvasive 
positive pressure ventilation (135). Risk does not correlate well with blebs or cysts (141). Among 
21 CF carriers, one had pneumothorax and others had respiratory symptoms including nasal 
polyps causing obstruction (142), however a larger study showed no difference in pneumothorax, 
sinusitis, or other respiratory conditions (143). 
Management of pneumothorax in CF is debated. Some suggest early surgical intervention 
(144, 145); others urge caution given potential future lung transplantation (146, 147). 
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Others 
There are reports of pneumothorax in other genetic syndromes. These include: Sotos 
syndrome (148), spinocerebellar ataxia type 1  (149), telomerase reverse transcriptase (TERT gene) 
mutations (emphysema and pneumothorax in smokers) (150), hereditary mucoepithelial dysplasia 
(151), and diffuse dendriform pulmonary ossification (152). 
A genetic approach to patients with spontaneous pneumothorax
Current clinical guidelines for the evaluation and management of pneumothorax do not 
address the familial, syndromic, or potentially syndromic cases (153, 154). We argue that 
establishing a genetic diagnosis is beneficial for patients and their relatives. For the index case, 
establishing a genetic etiology can guide pneumothorax management, including the need for 
pleurodesis after first pneumothorax. Moreover, given that the genetic forms of pneumothorax are 
associated with extra-pulmonary complications, a genetic diagnosis enables targeted surveillance 
and prophylaxis. Examples include blood pressure control and echocardiography in Marfan 
syndrome and surveillance for renal tumors in BHDS. The potential benefits to family – whether 
pneumothorax has occurred in other family members or not – are no less significant. Identification 
of a pathogenic genetic variant in the index case enables testing, counseling, and 
surveillance/prophylaxis in family members carrying the same variant. For these reasons, we 
recommend that an underlying genetic diagnosis be routinely entertained in patients with 
spontaneous pneumothorax.
Figure 3 provides a basic algorithm to evaluate this question, emphasizing the importance 
of a focused family history, targeted history taking and physical examination, and careful review 
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of imaging. Figure 4 provides a graphical representation of which findings are associated with 
which syndromes.
In addition to pneumothorax, the family history should ascertain associated lung diseases 
(particularly emphysema, bronchiectasis, and CF), abnormal chest imaging (cysts/blebs/bullae), 
renal tumors (observed in BHDS and TSC), physical features consistent with pneumothorax-
associated syndromes (see Table 1), and consanguinity (which could heighten suspicion for an 
autosomal recessive condition). While a positive family history can help flag patients, an absent 
family history should not dissuade pursuit of a genetic cause of pneumothorax; both FSP caused 
by FLCN mutations and dominant pneumothorax-associated syndromes can arise via de novo 
mutations (155) or display reduced penetrance, and autosomal recessive conditions frequently lack  
family history. 
History taking and physical examination should include focused screening for features of 
pneumothorax-associated genetic syndromes (Table 1). A thorough examination of the skin is 
essential, as dermatologic manifestations of BHDS are often subtle. Skeletal anomalies, 
hyperextensibility, and distinct facial features could suggest a connective tissue disorder. 
Current clinical guidelines do not recommend chest CT in first-time, unilateral spontaneous 
pneumothorax (153, 154). However, a recent study demonstrating the cost-effectiveness of CT to 
detect diffuse, cystic lung diseases in patients with first-time pneumothorax (156) is among the 
reasons some authors argue for the adoption of this practice (157). While acknowledging that the 
risk-benefit profile is unknown (11), we suggest considering chest CT in first-time pneumothorax 
if a family history is present or if the patient is female given that the mutational burden to cause 
pneumothorax in women appears to be higher (unpublished data) and because of the possibility of 
LAM. The presence of multiple (158) and/or non-apical cysts (11) may suggest BHDS or FLCN-
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related FSP. Parenchymal lung disease might suggest A1AT deficiency or LAM, and airways 
disease CF. Aortic pathology might suggest Marfan syndrome or Loeys-Dietz syndrome. 
We recommend genetic testing or evaluation in the following scenarios: An isolated family 
history of pneumothorax should prompt sequencing and deletion/duplication screening of FLCN. 
This will be positive in 17-50% of cases (5, 6). A family history of blebs/cysts/or bullae or a 
personal history of non-apical blebs/cysts/bullae should also prompt testing of FLCN. In the 
absence of positive family history and CT data, the merits of FLCN testing are not clear, although 
10% of these patients will have pathogenic mutations as well.  Should the personal or family 
medical history or the physical examination raise suspicion for a genetic syndrome, we recommend 
referral to a medical geneticist for a more detailed examination and consideration of genetic testing 
for pneumothorax-associated syndromes.
Summary
A genetic cause of pneumothorax can have high impact clinical implications. The 
generalist, emergency physician, radiologist, pulmonologist, surgeon, or other specialist, armed 
with the above recommendation, is enabled to raise the possibility of a genetic/familial diagnosis 
in pneumothorax patients. Additional studies – ideally prospective – that test the value of chest 
CT, genetic testing, and genetics referral to uncover genetic causes of pneumothorax, and the 
appropriateness of surgery after first-time pneumothorax, will enable the official “society” 
guidelines to be updated. Furthermore, yet-undiscovered genetic contributions to pneumothorax 
likely exist, which researchers will uncover in time via assembly and study of patient cohorts and 
by other methods. 
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Table 1. Mendelian diseases associated with spontaneous pneumothorax. 
AD, autosomal dominant. AR, autosomal recessive. P or PTX, pneumothorax. C, cysts.
Condition /
Inheritance pattern
Pulmonary features 
(in addition to pneumothorax) Extrapulmonary features 
Penetrance 
(PTX/Cysts) Gene(s)
Diagnostic 
criteria
Syndromes resulting from mutated tumor suppressor genes
Birt-Hogg-Dubé 
syndrome
AD
Cysts: Elliptical or lentiform, 
with predominantly basilar, 
medial, and subpleural 
distribution
Skin lesions: Fibrofolliculomas, trichodiscomas, acrochordons 
(skin tags)
Renal cancer: Renal cell carcinomas, oncocytomas, and others
P: 22-41%
C: 83-100%
FLCN (29)
Tuberous sclerosis 
complex
AD
LAM: Cysts, bullae, 
reticulonodular infiltrates, 
pleural effusions, obstructive 
physiology; female 
predominance
Micronodular pneumocyte 
hyperplasia
Brain: Subependymal nodules, cortical dysplasia (tubers), cerebral 
white matter migration lines, subependymal giant cell 
astrocytomas, seizures or infantile spasms, developmental delay/ 
intellectual disability, autism, ADHD
Skin: Hypopigmented macules (ash leaf spots), Shagreen patches, 
confetti lesions, facial angiofibromas, fibrous cephalic plaques, 
ungual fibromas
Kidney: Angiomyolipomas (renal or extra-renal), renal cysts, renal 
cell carcinomas & oncocytomas
Heart: Rhabdomyomas, arrhythmias
Eye: Retinal nodular hamartomas, achromic retinal patches
Mouth: Dental pits, intraoral fibromas
In LAM: 
P: 56-66% 
C: ~100%
TSC2
TSC1
(159)
Syndromes of disordered connective tissue
Marfan syndrome
AD
Lungs usually normal; rare 
features include:
Cysts
Emphysema
Congenital lung malformations
Increased TLC and RV
Skeletal: Tall, thin habitus, ↓ upper:lower segment ratio, reduced 
elbow extension, arachnodactyly, hand/wrist signs, pectus 
excavatum/carinatum, scoliosis/kyphosis, hindfoot deformity, flat 
feet
Facial features: Dolichocephaly, down-slanting palpebral fissures, 
enophthalmos, retrognathia, malar hypoplasia
Eye: Lens dislocation, severe myopia
Skin: Striae
Cardiac: Aortic dilation/dissection/aneurysm/ rupture, mitral valve 
prolapse
P: 4-11%
C: 10% 
(bullae / 
blebs)
FBN1 (160)
Vascular (type IV) 
Ehlers Danlos 
syndrome 
AD
Cavitary lesions
Cysts, bullae
Fibrous nodules with osseous 
metaplasia
Vascular: Arterial aneurysm, dissection, rupture, carotid-
cavernous sinus fistula
Organ rupture: of colon or gravid uterus
P: 16-80% COL3A1 (94)
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Hemo-pneumothorax or 
pulmonary hemorrhage  
Facial appearance: Thin lips and nose, micrognathia, prominent 
eyes
Skin: Translucent skin with visible veins, easy bruising
Orthopedic: Clubfoot, congenital hip dislocation, lax small joints, 
muscle/tendon rupture
Loeys-Dietz 
syndrome
AD
N/A Vascular: Arterial aneurysms, dissection, tortuosity
Skeletal: Pectus excavatum or carinatum, joint laxity or 
contractures, cervical spine instability, scoliosis, arachnodactyly, 
club foot
Craniofacial: Bifid uvula or cleft palate, hypertelorism, 
retrognathia
Cutaneous: Translucent or dystrophic skin, easy bruising
Uterine rupture
Unknown TGFBR1
TGFBR2
SMAD3
TGFB2
TGFB3
SMAD2 
None
Homocystinuria
AR
N/A Skeletal: Marfanoid habitus
Eye: Dislocated lens, myopia
Neurologic: Intellectual disability, seizures
Vascular: Thrombosis
Unknown CBS (161)
Cutis laxa*
AD/AR
*Note that features 
vary by subtype.
Bronchiectasis
Emphysema
Cutaneous: Redundant, loose, hypoelastic skin
Facial: Aged appearance
Vascular: Aortic aneurysms, tortuosity
Musculoskeletal: Joint laxity, scoliosis
Other: Hernias
Unknown ELN
FBLN4
FBLN5
LTBP4
N/A
Syndromes that disrupt lung architecture
Alpha-1-antitrypsin 
deficiency
AR
Panacinar emphysema 
Bullae
Bronchiectasis
Obstruction
Liver : Cirrhosis, hepatocellular carcinoma, neonatal cholestatic 
jaundice
Skin: Panniculitis
Inflammatory: Vasculitis
Unknown SERPIN
A1
(162)
Cystic fibrosis
AR
Bronchiectasis
Bacterial colonization/infection
Cysts/cavitations
Obstruction
Respiratory failure
GI: Meconium ileus, pancreatic insufficiency, pancreatitis, 
malabsorption, failure to thrive
Male infertility
ENT: Nasal polyps, sinus disease
P: 8% CFTR (163)
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Figures
Figure 1. Pedigrees demonstrating familial spontaneous pneumothorax. a. Most pedigrees are 
consistent with autosomal dominant inheritance with incomplete penetrance. No causal gene 
reported for this family. Circles, females; squares, males; shaded, pneumothorax. Reproduced 
from (21). b. Some pedigrees are also consistent with X-linked recessive inheritance (versus AD 
with reduced penetrance in females). No causal gene reported for this family. Dot, obligate carrier. 
Reproduced from (4) c. Family with known FLCN mutation. CT lung findings (black shading) are 
more clearly autosomal dominant than pneumothorax (arrows). Individual 23 has a different bullae 
phenotype (apical instead of random distribution) and is mutation negative, likely explaining why 
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his mother does not have bullae (different cause of pneumothorax in this branch of family). *, CT 
lung performed; diagonal line, deceased. Reproduced from (26). 
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Figure 2. Physical exam findings of pneumothorax-associated syndromes. (a-c) Birt-Hogg-
Dubé syndrome (BHDS). a. Fibrofolliculomas of the neck (164). b. Lung cysts and bullae; extra-
apical location is characteristic (164). c. Pleural blebs on the surface of the left lower lobe; these 
can be missed on CT but seen during thoracoscopy/VATS (164). (d-j) Marfan syndrome. d. 
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Marfanoid body habitus (90). e. Scoliosis, striae, reduced elbow extension (165). f. Positive thumb 
and wrist signs indicating arachnodactyly (165). g. Lens dislocation (166). h. Pectus excavatum 
(165). i. Hindfoot deformity (165). (j) Vascular (type IV) EDS. j. Translucent skin on the torso of 
an infant (167). (k) Loeys-Dietz syndrome. k. Bifid uvula (168) (l-m) Alpha-1-antitrypsin 
deficiency. l. Panlobular emphysema (case courtesy of Dr. Jeremy Jones, Radiopaedia.org, 
rID:13441). m. Panniculitis (169). (n) Cutis laxa. n. Autosomal recessive cutis laxa IIa (170). (o-
p) Homocystinuria. o. Chest wall deformity (171). p. Lens dislocation (172). (q-y) Tuberous 
sclerosis complex. q. hypopigmented macules (ash leaf spots) (159). r. angiofibromas (159). s. 
fibrous plaques (159). t. Ungual fibromas (159). u. Retinal hamartoma (159). v. Shagreen patch 
(159). w. Cortical dysplasia (tubers, white arrows; radial migration lines, black arrows) (159). x. 
Lymphangioleiomyomatosis (159). y. Multifocal micronodular pneumocyte hyperplasia (173). 
Images are reproduced from the sources cited above.
Page 48 of 50 AJRCCM Articles in Press. Published on 25-January-2019 as 10.1164/rccm.201807-1212CI 
 Copyright © 2019 by the American Thoracic Society 
49
Figure 3. Proposed algorithm for identifying spontaneous pneumothoraces with a genetic 
basis. Algorithm should be applied to all patients with spontaneous pneumothorax. Dashed arrows 
are optional, based on the practitioner’s comfort. *FLCN testing in cases of absent family history 
is still reasonable, so long as a chest CT, if previously obtained, is not inconsistent with BHDS.  
**Chest CT findings in BHDS include bilateral, multifocal, predominately lower-lobe cysts.
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Figure 4. History, physical exam, and imaging findings that raise the possibility of a 
syndromic cause of pneumothorax. Syndromes predisposing to pneumothorax (X-axis) are 
intersected with their major features (Y-axis). Personal history/ family history/ physical exam 
findings are in blue. Imaging findings are in maroon. The skin findings of BHDS are age dependent; 
thus, skin exams of the parents or even grandparents may at times more informative than for the 
proband. BHDS, Birt-Hogg-Dubé syndrome; TSC-LAM, lymphangioleiomyomatosis in an 
individual with tuberous sclerosis; CF, cystic fibrosis; A1ATD, alpha-1-antitrypsin deficiency; 
vEDS, vascular Ehlers-Danlos syndrome; LDS, Loeys-Dietz syndrome.
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